How Effective Are Secretagogues for Irritable Bowel Syndrome With Constipation
The pooled population prevalence of irritable bowel syndrome (IBS) has been estimated at 11.2%.1 Until the turn of the century, treatment options with convincing evidence of effectiveness were lacking.2 Since then, new therapeutic options have emerged, including intestinal secretagogues for the treatment of IBS with constipation (IBS-C), which accounts for approximately 40% of patients with IBS.3 Secretagogues are agents that increase luminal water content through the activation of chloride secretion by the chloride channel type-2 (lubiprostone), through activation of the guanylate cyclase receptor and the cystic fibrosis transmembrane conductance regulator channel (linaclotide, plecanatide), or through inhibition of sodium reuptake by the sodium-hydrogen exchanger-3 (tenapanor).
Source: Gastroenterology - Category: Gastroenterology Authors: Jasper Pannemans, Jan Tack Tags: Editorial Source Type: research
More News: Chloride | Constipation | Cystic Fibrosis | Gastroenterology | Irritable Bowel Syndrome | Sodium